Back to Research

Organization profile

Amporin Pharmaceuticals

Amporin Pharmaceuticals is a Swiss clinical-stage biotechnology startup that develops first-in-class small molecule drugs to target the amyloid pores responsible for neurodegenerative cell death. The company’s vision is to provide acute oral disease-modifying treatments for major conditions such as Parkinson's disease and ALS by repairing cellular membranes and restoring homeostasis.

Basel, SwitzerlandFounded 2024

Overview

1. Executive Summary (Confidence: High)

Amporin Pharmaceuticals is a high-potential entrant in the longevity and neurodegeneration sectors, founded in April 2024 in Basel, Switzerland. The organization is pioneering a breakthrough scientific approach that shifts the therapeutic focus away from insoluble amyloid fibrils—which have largely failed in clinical trials—toward toxic soluble misfolded protein oligomers. These oligomers aggregate into "amyloid pores" that puncture holes in cell membranes, causing a lethal influx of calcium and subsequent degeneration. Amporin's leadership team, consisting of Big Pharma veterans from Roche, Novartis, and various biotechs, is developing a pipeline of small molecule inhibitors categorized as Amporbans, Amporins, and Amportacs. Having already secured seed validation through the Venture Kick program, the organization is currently building a robust in vitro data package to support its first clinical targets in Parkinson's and ALS.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.